The briefing
A Phase III clinical trial published in JAMA reported that nicotinamide riboside led to worse outcomes than placebo in early Parkinson’s disease. The findings urge caution regarding the supplement’s use in this setting.
Original headline
NOPARK trial finds nicotinamide riboside worsens outcomes versus placebo in early Parkinson disease